At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that evaluated the safety and efficacy of the PI3Kδ inhibitor, idelalisib, in combination with chemoimmunotherapy for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Investigated combinations include idelalisib in combination with rituximab; ofatumumab; bendamustine and rituximab; fludarabine; and chlorambucil.
Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL
23rd July 2015
Oncology
>